Man in violation of privacy law

Breaking news and expert analysis on legal and compliance issues

[Back To Home][Back To Archives]

From Antitrust Law Daily, November 6, 2014

Pharmacies dismissed from Lipitor suit for implausible reverse payment claims

By Greg Hammond, J.D.

A number of pharmacy plaintiffs were unable to demonstrate that Ranbaxy Laboratories Ltd. and Pfizer, Inc. entered into a reverse payment settlement agreement (RPSA) that blocked generic competition for the pharmaceutical drug atorvastatin calcium sold under the brand name Lipitor. The federal district court in Trenton, New Jersey therefore dismissed the pharmacies’ complaint (In re Lipitor Antitrust Litigation, November 5, 2014, Sheridan, P.).

The pharmacy plaintiffs alleged that Ranbaxy and Pfizer entered into an illegal RPSA in 2008 by signing a settlement agreement in which Pfizer gave substantial financial inducements to Ranbaxy, in exchange for Ranbaxy’s agreement to delay its launch of generic Lipitor until November 30, 2011. The financial inducements included: (1) Pfizer’s “sweetheart” agreement to dismiss damages claims likely worth hundreds of millions of dollars in Accupril litigation, in exchange for a token “pretextual” payment of $1 million; and (2) the right to market generic Lipitor in at least 11 foreign markets outside the United States.

According to the court, the pharmacy plaintiffs failed to calculate the reasonable valuation of the Pfizer/Ranbaxy alleged reverse payment. Rather, the pharmacies merely relied on one or two statements made by Pfizer executives regarding the facts underlying their claims. In previously dismissing direct purchaser plaintiffs’ claims in this case, the court determined that the one or two statements made by Pfizer executives were insufficient to plausibly state their reverse payment claims. Consequently, the pharmacy plaintiffs’ complaint, which attempts to prove a per se market allocation theory under California law, was deemed implausible in light of the court’s previous ruling.

The case number is 3:12-cv-02389 (PGS).

Attorneys: Gil D. Messina (Messina Law Firm) and Joseph M. Alioto (Alioto Law Firm) for RP Healthcare, Inc. Brendan G. Woodard (White & Case LLP) for Pfizer Inc.

Companies: Pfizer Inc.; Ranbaxy; RP Healthcare, Inc.

MainStory: TopStory Antitrust NewJerseyNews

Antitrust Law Daily

Introducing Wolters Kluwer Antitrust Law Daily — a daily reporting service created by attorneys, for attorneys — providing same-day coverage of breaking news, court decisions, legislation, and regulatory activity.


A complete daily report of the news that affects your world

  • View full summaries of federal and state court decisions.
  • Access full text of legislative and regulatory developments.
  • Customize your daily email by topic and/or jurisdiction.
  • Search archives for stories of interest.

Not just news — the right news

  • Get expert analysis written by subject matter specialists—created by attorneys for attorneys.
  • Track law firms and organizations in the headlines with our new “Who’s in the News” feature.
  • Promote your firm with our new reprint policy.

24/7 access for a 24/7 world

  • Forward information with special copyright permissions, encouraging collaboration between counsel and colleagues.
  • Save time with mobile apps for your BlackBerry, iPhone, iPad, Android, or Kindle.
  • Access all links from any mobile device without being prompted for user name and password.